Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Michel Eichelbaum
Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated With Tamoxifen
Frontiers in Pharmacology
Pharmacology
ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity After Renal Transplantation
Journal of the American Society of Nephrology : JASN
Medicine
Nephrology
Related publications
Comprehensive CYP2D6 Genotype and Adherence Affect Outcome in Breast Cancer Patients Treated With Tamoxifen Monotherapy
Breast Cancer Research and Treatment
Cancer Research
Oncology
Pcn191 - Cost-Effectiveness of Monitoring Endoxifen Levels in Breast Cancer Patients Adjuvantly Treated With Tamoxifen
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Limited Predictive Value of Achieving Beneficial Plasma (Z)-Endoxifen Threshold Level by CYP2D6 Genotyping in Tamoxifen-Treated Polish Women With Breast Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Prevalent Breast Cancer Patients With a Homozygous Mutant Status for CYP2D6*4: Response and Biomarkers in Tamoxifen Users
Breast Cancer Research and Treatment
Cancer Research
Oncology
Pharmacogenetics and Breast Cancer Endocrine Therapy: CYP2D6 as a Predictive Factor for Tamoxifen Metabolism and Drug Response?
Expert Reviews in Molecular Medicine
Molecular Medicine
Molecular Biology
CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality
Clinical Pharmacology and Therapeutics
Pharmacology
Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients
Journal of Clinical Pharmacology
Pharmacology
CYP2D6 Genotyping and Tamoxifen in the Treatment of Post-Menopausal Breast Cancer - A Reply
British Journal of Clinical Pharmacology
Pharmacology
Persistence in Patients With Breast Cancer Treated With Tamoxifen or Aromatase Inhibitors- Analysis Based on Oncology Analyzer Database
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
